Novo Nordisk Lifts Guidance as Blockbuster Drug Demand Shows No Signs of Abating

By Dominic Chopping

Danish pharmaceutical giant Novo Nordisk raised full-year guidance to reflect better pricing in the U.S. and as global demand for its hit weight-loss and diabetes drugs continues to outstrip supply.

The company said Thursday that sales of its blockbuster Ozempic diabetes drug rose 42% on the year in the first quarter, while sales of obesity treatment Wegovy more than doubled.

Write to Dominic Chopping at dominic.chopping@wsj.com